Janus kinase inhibition and symptom control in myeloproliferative neoplasms

Prithviraj Bose; Mahesh Swaminathan

doi:10.1080/03007995.2018.1438999

Janus kinase inhibition and symptom control in myeloproliferative neoplasms

Prithviraj Bose, Mahesh Swaminathan

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	935-937
Number of pages	3
Journal	Current Medical Research and Opinion
Volume	34
Issue number	5
DOIs	https://doi.org/10.1080/03007995.2018.1438999
State	Published - May 4 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1080/03007995.2018.1438999

Cite this

@article{5c6aac20e48744c6b00f8b6313be6192,

title = "Janus kinase inhibition and symptom control in myeloproliferative neoplasms",

author = "Prithviraj Bose and Mahesh Swaminathan",

note = "Funding Information: This work was supported in part by the MD Anderson Cancer Center support grant P30 CA016672 from the National Cancer Institute (National Institutes of Health). Funding Information: M.S. has no financial disclosures. P.B. has received research support from Incyte corporation, Celgene corporation, CTI Biopharma, Blueprint Medicines Corporation, Astellas, and Pfizer.",

year = "2018",

month = may,

day = "4",

doi = "10.1080/03007995.2018.1438999",

language = "English (US)",

volume = "34",

pages = "935--937",

journal = "Current Medical Research and Opinion",

issn = "0300-7995",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Janus kinase inhibition and symptom control in myeloproliferative neoplasms

AU - Bose, Prithviraj

AU - Swaminathan, Mahesh

N1 - Funding Information: This work was supported in part by the MD Anderson Cancer Center support grant P30 CA016672 from the National Cancer Institute (National Institutes of Health). Funding Information: M.S. has no financial disclosures. P.B. has received research support from Incyte corporation, Celgene corporation, CTI Biopharma, Blueprint Medicines Corporation, Astellas, and Pfizer.

PY - 2018/5/4

Y1 - 2018/5/4

UR - http://www.scopus.com/inward/record.url?scp=85043689157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043689157&partnerID=8YFLogxK

U2 - 10.1080/03007995.2018.1438999

DO - 10.1080/03007995.2018.1438999

M3 - Comment/debate

C2 - 29415577

AN - SCOPUS:85043689157

SN - 0300-7995

VL - 34

SP - 935

EP - 937

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

IS - 5

ER -

Janus kinase inhibition and symptom control in myeloproliferative neoplasms

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this